Clinical trial
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator…
NCT02346240 · UCB Biopharma S.P.R.L., Industry · Completed
Key facts
| NCT number | NCT02346240 |
|---|---|
| Title | Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Acronym | CIMPACT |
| Lead sponsor | UCB Biopharma S.P.R.L., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis, Plaque Psoriasis |
| Intervention type | Biological, Other |
| Interventions | Certolizumab Pegol, Etanercept, Placebo |
| Enrollment | 559 |
| Start date | Feb 11, 2015 |
| Primary completion | Mar 22, 2016 |
| Completion | Dec 17, 2018 |
| First posted | Jan 26, 2015 |
| Last update posted | Jul 16, 2021 |
| Countries | Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: